Showing results (41-50 of 1,225) with videos related to

Sort By:
Pageof 123
Cancer Treatment and Research Communications|February 11, 2026
Surviving the siege: A review on the metabolic hallmarks of cancer dormancyFarah Djelti, Mostefa Hani, Yazid Chetbani, et al.
Cancer Treatment and Research Communications|February 7, 2026
Precision oncology in Bulgaria: a prospective study of metastatic colorectal cancer patientsGeorge Dimitrov, Zornitsa Kamburova, Krassimir Petrov, et al.
Cancer Treatment and Research Communications|February 3, 2026
Clinical characteristics and prognostic outcomes in KRAS-mutant non-small cell lung cancer: A real-world study with or without COPD comorbidityChen Liao, Yubo Wang, Zhoukui Bi, et al.
Cancer Treatment and Research Communications|January 29, 2026
OTUB1/SLC7A11 axis promoted AKT signaling activation to mediate ovarian cancer progressionYujin Zhang, Jing Wang, Sensen Sun, et al.
Cancer Treatment and Research Communications|January 28, 2026
Chemotherapy-induced liver injury in Tibetan breast cancer patients: clinical features and risk factor analysisQuzhen Ciren, Zhen Se, Wangmu Sangdan, et al.
Cancer Treatment and Research Communications|January 16, 2026
Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitorsHiroki Ito, Masayuki Shirasawa, Yuki Akazawa, et al.
Cancer Treatment and Research Communications|March 27, 2025
Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in CanadaWilliam J Phillips, Horia Marginean, Mohammad Alrehaili, et al.
Cancer Treatment and Research Communications|March 26, 2025
A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in TaiwanKuo-Ting Lee, Po-Hsiang Huang, Chih-Yi Hsu, et al.
Cancer Treatment and Research Communications|March 18, 2025
Relationship between p53 protein and ER, PR status in breast cancer tissueFang Zhang
Cancer Treatment and Research Communications|November 26, 2018
First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancerKazuma Kishi, Hiroshi Sakai, Takashi Seto, et al.
Pageof 123